alendronate has been researched along with Osteonecrosis in 107 studies
alendronic acid : A 1,1-bis(phosphonic acid) that is methanebis(phosphonic acid) in which the two methylene hydrogens are replaced by hydroxy and 3-aminopropyl groups.
Osteonecrosis: Death of a bone or part of a bone, either atraumatic or posttraumatic.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To conduct a literature review on sodium alendronate, focusing on osteonecrosis of the jaws, a serious potential side effect." | 8.91 | Important aspects concerning alendronate-related osteonecrosis of the jaws: a literature review. ( Cherubini, K; Figueiredo, MA; Iglesias, JE; Salum, FG, 2015) |
| "The purpose of the current review was to determine the efficacy of alendronate for preventing collapse of femoral head in adult patients with nontraumatic avascular osteonecrosis of femoral head (ANFH)." | 8.90 | Efficacy of alendronate for preventing collapse of femoral head in adult patients with nontraumatic osteonecrosis. ( Hong, YC; Lin, T; Luo, RB; Shi, JB; Zhong, HM, 2014) |
| "We aimed to establish the incidence of alendronate-related osteonecrosis of the jaw (ONJ) in the southeast of Scotland, and to assess the effect of corticosteroids on it." | 7.83 | Epidemiological study of alendronate-related osteonecrosis of the jaw in the southeast of Scotland. ( Lopes, V; Malden, N; Ralston, S; Sammut, S, 2016) |
| "This work aimed at determining whether bisphosphonate therapy produces a sufficient condition for jaw osteonecrosis after tooth extraction." | 7.77 | Association between bisphosphonates and jaw osteonecrosis: a study in Wistar rats. ( Azambuja, AA; Campos, MM; Cherubini, K; Maahs, MP; Salum, FG, 2011) |
| "The aim of this study was to evaluate a possible role of microcracks in the pathogenesis of bisphosphonate-related osteonecrosis of the jaw (ONJ) and to discuss an etiological model." | 7.76 | Importance of microcracks in etiology of bisphosphonate-related osteonecrosis of the jaw: a possible pathogenetic model of symptomatic and non-symptomatic osteonecrosis of the jaw based on scanning electron microscopy findings. ( Eufinger, H; Hoefert, S; Schmitz, I; Tannapfel, A, 2010) |
| "Several recent medical articles have described multiple cases of unusual low-impact subtrochanteric stress fractures or completed fractures of the femur in patients who have been on the bisphosphonate alendronate for several years for osteoporosis or osteopenia." | 7.75 | Bisphosphonates and low-impact femoral fractures: current evidence on alendronate-fracture risk. ( Schneider, JP, 2009) |
| "Bisphosphonate use, in particular pamidronate, improved pain scores, analgesic requirement and musculoskeletal function in patients with osteonecrosis occurring as a complication of childhood ALL therapy." | 5.14 | Use of bisphosphonates for the treatment of osteonecrosis as a complication of therapy for childhood acute lymphoblastic leukaemia (ALL). ( Carter, T; Cole, C; Kotecha, RS; Lee, SJ; Murray, KJ; Powers, N, 2010) |
| "To conduct a literature review on sodium alendronate, focusing on osteonecrosis of the jaws, a serious potential side effect." | 4.91 | Important aspects concerning alendronate-related osteonecrosis of the jaws: a literature review. ( Cherubini, K; Figueiredo, MA; Iglesias, JE; Salum, FG, 2015) |
| "The purpose of the current review was to determine the efficacy of alendronate for preventing collapse of femoral head in adult patients with nontraumatic avascular osteonecrosis of femoral head (ANFH)." | 4.90 | Efficacy of alendronate for preventing collapse of femoral head in adult patients with nontraumatic osteonecrosis. ( Hong, YC; Lin, T; Luo, RB; Shi, JB; Zhong, HM, 2014) |
| " Usually with alendronate the risk of bisphosphonate-related osteonecrosis of jaw (BRONJ) wears off after 12 months." | 3.96 | Osteonecrosis and spontaneous exfoliation of dental implants associated with oral bisphosphonate therapy: a case report. ( Hilal, G; Rawal, SY, 2020) |
| "We aimed to establish the incidence of alendronate-related osteonecrosis of the jaw (ONJ) in the southeast of Scotland, and to assess the effect of corticosteroids on it." | 3.83 | Epidemiological study of alendronate-related osteonecrosis of the jaw in the southeast of Scotland. ( Lopes, V; Malden, N; Ralston, S; Sammut, S, 2016) |
| "Between 2006 and 2009, 17 consecutive patients (mean age 68 years) with clinical and radiographic signs of knee osteonecrosis were identified and given alendronate, 70 mg perorally, once a week for a minimum of 6 months." | 3.78 | Treatment of spontaneous osteonecrosis of the knee (SPONK) by a bisphosphonate. ( Geijer, M; Jureus, J; Lindstrand, A; Roberts, D; Tägil, M, 2012) |
| "This work aimed at determining whether bisphosphonate therapy produces a sufficient condition for jaw osteonecrosis after tooth extraction." | 3.77 | Association between bisphosphonates and jaw osteonecrosis: a study in Wistar rats. ( Azambuja, AA; Campos, MM; Cherubini, K; Maahs, MP; Salum, FG, 2011) |
| "twenty-three ONJ patients had taken alendronate for osteoporosis treatment, and the s-CTX testing results were low levels of 10-192 pg/ml (mean: 93." | 3.77 | Retrospective study of two biochemical markers for the risk assessment of oral bisphosphonate-related osteonecrosis of the jaws: can they be utilized as risk markers? ( Chung, DJ; Kim, DY; Kwon, YD; Ohe, JY; Park, YD, 2011) |
| "The aim of this study was to evaluate a possible role of microcracks in the pathogenesis of bisphosphonate-related osteonecrosis of the jaw (ONJ) and to discuss an etiological model." | 3.76 | Importance of microcracks in etiology of bisphosphonate-related osteonecrosis of the jaw: a possible pathogenetic model of symptomatic and non-symptomatic osteonecrosis of the jaw based on scanning electron microscopy findings. ( Eufinger, H; Hoefert, S; Schmitz, I; Tannapfel, A, 2010) |
| "These results suggest that etidronate may 1) inhibit the entry of NBPs into cells related to inflammation and/or necrosis, 2) inhibit the binding of NBPs to bone hydroxyapatite, 3) at least partly eliminate (or substitute for) NBPs that have already accumulated within bones, and thus 4) if used as a substitution drug for NBPs, be effective at treating or preventing NBP-associated osteonecrosis of the jaw." | 3.76 | Inhibition of necrotic actions of nitrogen-containing bisphosphonates (NBPs) and their elimination from bone by etidronate (a non-NBP): a proposal for possible utilization of etidronate as a substitution drug for NBPs. ( Endo, Y; Funayama, H; Kawamura, H; Kumamoto, H; Kuroishi, T; Oizumi, T; Sasaki, K; Sugawara, S; Takahashi, H; Yamaguchi, K; Yamamoto, M; Yokoyama, M, 2010) |
| "Several recent medical articles have described multiple cases of unusual low-impact subtrochanteric stress fractures or completed fractures of the femur in patients who have been on the bisphosphonate alendronate for several years for osteoporosis or osteopenia." | 3.75 | Bisphosphonates and low-impact femoral fractures: current evidence on alendronate-fracture risk. ( Schneider, JP, 2009) |
| "Recently, some reports indicate that osteonecrosis of the jaws could occur after taking drugs containing hisphosphonates, including alendronate, pamidronate and zolendronate, which are widely used to treat osteoporosis and metastatic skeletal lesions in clinic." | 3.73 | [Advances in the research of bisphosphonate-associated osteonecrosis of the jaws]. ( Ji, T; Ruan, M; Zhang, CP, 2006) |
| "The name, osteonecrosis, is misleading because the primary histopathological lesion is osteocyte apoptosis." | 2.48 | Glucocorticoid-induced osteonecrosis. ( Weinstein, RS, 2012) |
| "They are indicated for the treatment of osteoporosis." | 2.44 | Osteochemonecrosis of jaws and bisphosphonates. ( Beirne, JC; Khosa, AD; Nayyar, MS, 2007) |
| "etidronate) have been associated with acute renal failure." | 2.44 | Safety considerations with bisphosphonates for the treatment of osteoporosis. ( Civitelli, R; Emkey, R; Strampel, W, 2007) |
| " The variety of bisphosphonates currently available to us provides a wide range of tolerability and dosing profiles thus necessitating a thorough comparison of the most recent oral and intravenous bisphosphonates to differentiate the clinical context in which they should be used." | 2.43 | Tolerability of different dosing regimens of bisphosphonates for the treatment of osteoporosis and malignant bone disease. ( Adachi, JD; Beattie, K; Bobba, RS; Kumbhare, D; Parkinson, B, 2006) |
| "There are very few cases of pathological fracture induced by pancreatitis that affect the vertebrae." | 1.37 | Pathological fracture due to vertebral osteonecrosis associated with pancreatitis. ( Baba, T; Kaneko, H; Shitoto, K; Yoshioka, C, 2011) |
| "Alendronate was the most frequently implicated (six cases) and risedronate (five cases)." | 1.36 | [Jaw osteonecrosis induced by oral biphosphonates: 12 cases]. ( Barrier, A; Descroix, V; Goudot, P; Lescaille, G; Rigolet, A; Ruhin, B, 2010) |
| " Twelve patients who presented with exposed bone associated with bisphosphonates were reviewed to determine the type, dosage and duration of their bisphosphonate therapy, presenting findings, comorbidities and the event that incited the bone exposure." | 1.34 | Bisphosphonate-associated osteonecrosis of the jaw in patients with multiple myeloma and breast cancer. ( Alati, C; Allegra, A; Alonci, A; Cicciù, M; De Ponte, FS; Musolino, C; Nastro, E; Oteri, G; Quartarone, E, 2007) |
| "No osteonecrosis was noted immediately postoperatively or during the follow-up period in 61 patients." | 1.34 | Implant placement with or without simultaneous tooth extraction in patients taking oral bisphosphonates: postoperative healing, early follow-up, and the incidence of complications in two private practices. ( Fugazzotto, PA; Jaffin, R; Kumar, A; Lightfoot, WS, 2007) |
| "Sixty-two (52." | 1.33 | Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. ( Broumand, V; Fortin, M; Marx, RE; Sawatari, Y, 2005) |
| " Current reports have focused on therapy-resistant osteonecrosis of the jaws as a possible side effect of bisphosphonates." | 1.33 | [Osteonecrosis of the jaws as a possible adverse effect of the use of bisphosphonates]. ( Eufinger, H; Hoefert, S, 2005) |
| "Here we report 29 cases of bone necrosis of the jaws in patients treated with pamidronate (Aredia), zoledronate (Zometa) and alendronate: 15 underwent surgical procedures and 14 occurred spontaneously." | 1.33 | Bone necrosis of the jaws associated with bisphosphonate treatment: a report of twenty-nine cases. ( Bonaninil, M; Corcione, L; Corradi, D; D'Aleo, P; Ferrari, S; Guidotti, R; Manfredi, M; Meleti, M; Merigo, E; Poli, T; Ripasarti, A; Sesenna, E; Vescovi, P; Zanzucchi, E, 2006) |
| "As revascularization follows, bone resorption may lead to collapse in load bearing areas during the remodeling." | 1.32 | Alendronate prevents collapse in mechanically loaded osteochondral grafts: a bone chamber study in rats. ( Aspenberg, P; Astrand, J; Tägil, M; Westman, L, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 62 (57.94) | 29.6817 |
| 2010's | 43 (40.19) | 24.3611 |
| 2020's | 2 (1.87) | 2.80 |
| Authors | Studies |
|---|---|
| Rawal, SY | 1 |
| Hilal, G | 1 |
| Rong, K | 1 |
| Li, X | 1 |
| Jiang, W | 1 |
| Wu, X | 1 |
| Xia, Q | 1 |
| Chen, J | 1 |
| Yin, X | 1 |
| Basile, P | 1 |
| Falk, N | 1 |
| Khominsky, A | 1 |
| Lim, M | 1 |
| Agarwala, S | 1 |
| Vijayvargiya, M | 1 |
| Chiu, WY | 1 |
| Lee, JJ | 1 |
| Tsai, KS | 1 |
| Peled, E | 1 |
| Bejar, J | 1 |
| Barak, M | 1 |
| Orion, E | 1 |
| Norman, D | 1 |
| Ulmner, M | 1 |
| Jarnbring, F | 1 |
| Törring, O | 1 |
| Iglesias, JE | 1 |
| Salum, FG | 2 |
| Figueiredo, MA | 1 |
| Cherubini, K | 2 |
| Vaishya, R | 1 |
| Vijay, V | 1 |
| Vaish, A | 1 |
| Hong, YC | 1 |
| Luo, RB | 1 |
| Lin, T | 1 |
| Zhong, HM | 1 |
| Shi, JB | 1 |
| Yuan, H | 1 |
| Tanaka, J | 1 |
| Kokuryo, S | 1 |
| Yoshiga, D | 1 |
| Tsurushima, H | 1 |
| Sakaguchi, O | 1 |
| Habu, M | 1 |
| Nishihara, T | 1 |
| Yoshioka, I | 1 |
| Tominaga, K | 1 |
| Kaipatur, N | 1 |
| Major, P | 1 |
| Stevenson, T | 1 |
| Pehowich, D | 1 |
| Adeeb, S | 1 |
| Doschak, M | 1 |
| Amin, NL | 1 |
| James, RM | 1 |
| Phillips, R | 1 |
| Sammut, S | 1 |
| Malden, N | 1 |
| Lopes, V | 1 |
| Ralston, S | 1 |
| Wong, YK | 1 |
| Cheng, JC | 1 |
| Lehrer, S | 1 |
| Montazem, A | 1 |
| Ramanathan, L | 1 |
| Pessin-Minsley, M | 1 |
| Pfail, J | 1 |
| Stock, RG | 1 |
| Kogan, R | 1 |
| Sedghizadeh, PP | 1 |
| Stanley, K | 1 |
| Caligiuri, M | 1 |
| Hofkes, S | 1 |
| Lowry, B | 1 |
| Shuler, CF | 1 |
| Barrow, SY | 1 |
| Thomas, MV | 1 |
| Straus, SE | 1 |
| Aragon-Ching, JB | 1 |
| Ning, YM | 1 |
| Chen, CC | 1 |
| Latham, L | 1 |
| Guadagnini, JP | 1 |
| Gulley, JL | 1 |
| Arlen, PM | 1 |
| Wright, JJ | 1 |
| Parnes, H | 1 |
| Figg, WD | 1 |
| Dahut, WL | 1 |
| Geusens, P | 1 |
| Schneider, JP | 1 |
| Lazarovici, TS | 2 |
| Yahalom, R | 1 |
| Taicher, S | 1 |
| Elad, S | 1 |
| Hardan, I | 1 |
| Yarom, N | 2 |
| Kallmes, DF | 1 |
| Rad, AE | 1 |
| Gray, LA | 1 |
| McDonald, RJ | 1 |
| Clarke, BL | 1 |
| Stanton, DC | 1 |
| Balasanian, E | 1 |
| Magliocca, KR | 1 |
| Stavropoulos, MF | 1 |
| Bhattacharyya, I | 1 |
| Cohen, DM | 1 |
| Zahrowski, JJ | 1 |
| Kwon, YD | 3 |
| Kim, YR | 1 |
| Choi, BJ | 1 |
| Lee, DW | 1 |
| Kim, DY | 3 |
| Harada, A | 1 |
| Hikita, H | 1 |
| Miyazawa, K | 1 |
| Tabuchi, M | 1 |
| Kimura, M | 1 |
| Goto, S | 1 |
| Kunchur, R | 1 |
| Need, A | 1 |
| Hughes, T | 1 |
| Goss, A | 1 |
| Wongchuensoontorn, C | 1 |
| Liebehenschel, N | 1 |
| Wagner, K | 1 |
| Fakler, O | 1 |
| Gutwald, R | 1 |
| Schmelzeisen, R | 1 |
| Sauerbier, S | 1 |
| O'Ryan, FS | 2 |
| Khoury, S | 1 |
| Liao, W | 1 |
| Han, MM | 1 |
| Hui, RL | 2 |
| Baer, D | 1 |
| Martin, D | 2 |
| Liberty, D | 1 |
| Lo, JC | 2 |
| Hoefert, S | 2 |
| Schmitz, I | 1 |
| Tannapfel, A | 1 |
| Eufinger, H | 2 |
| Bocanegra-Pérez, S | 1 |
| Vicente-Barrero, M | 1 |
| Sosa-Henríquez, M | 1 |
| Gebaguer Blanco, A | 1 |
| Knezevic, M | 1 |
| Castellano-Navarro, JM | 1 |
| Burr, DB | 2 |
| Allen, MR | 2 |
| Moynihan, R | 2 |
| Gordon, NP | 1 |
| Yang, J | 1 |
| Hutchinson, M | 1 |
| Lathon, PV | 1 |
| Sanchez, G | 1 |
| Silver, P | 1 |
| Chandra, M | 1 |
| McCloskey, CA | 1 |
| Staffa, JA | 1 |
| Willy, M | 1 |
| Selby, JV | 1 |
| Go, AS | 1 |
| Ohe, JY | 2 |
| Yoo, JY | 1 |
| Walter, C | 1 |
| Kotecha, RS | 1 |
| Powers, N | 1 |
| Lee, SJ | 1 |
| Murray, KJ | 1 |
| Carter, T | 1 |
| Cole, C | 1 |
| Gates, BJ | 1 |
| Sonnett, TE | 1 |
| Duvall, CA | 1 |
| Dobbins, EK | 1 |
| Oizumi, T | 1 |
| Funayama, H | 1 |
| Yamaguchi, K | 1 |
| Yokoyama, M | 1 |
| Takahashi, H | 1 |
| Yamamoto, M | 1 |
| Kuroishi, T | 1 |
| Kumamoto, H | 1 |
| Sasaki, K | 1 |
| Kawamura, H | 1 |
| Sugawara, S | 1 |
| Endo, Y | 1 |
| Baba, T | 1 |
| Shitoto, K | 1 |
| Yoshioka, C | 1 |
| Kaneko, H | 1 |
| Treister, NS | 1 |
| Friedland, B | 1 |
| Woo, SB | 2 |
| Kraenzlin, ME | 1 |
| Graf, C | 1 |
| Meier, C | 1 |
| Kraenzlin, C | 1 |
| Friedrich, NF | 1 |
| Chiu, CT | 1 |
| Chiang, WF | 1 |
| Chuang, CY | 1 |
| Chang, SW | 1 |
| Kuijpers, SC | 1 |
| van Roessel, EW | 1 |
| van Merkesteyn, JP | 1 |
| Migliorati, CA | 1 |
| Mattos, K | 1 |
| Palazzolo, MJ | 1 |
| Scoletta, M | 1 |
| Arduino, PG | 2 |
| Dalmasso, P | 1 |
| Broccoletti, R | 2 |
| Mozzati, M | 1 |
| Hunter, SA | 1 |
| Orheim, R | 1 |
| Sazon, M | 1 |
| Newman, H | 1 |
| Woll, JE | 1 |
| Bergevin, M | 1 |
| Barrier, A | 1 |
| Lescaille, G | 1 |
| Rigolet, A | 1 |
| Descroix, V | 1 |
| Goudot, P | 1 |
| Ruhin, B | 1 |
| Maahs, MP | 1 |
| Azambuja, AA | 1 |
| Campos, MM | 1 |
| Pozzi, S | 1 |
| Raje, N | 1 |
| Fedele, S | 1 |
| Porter, SR | 1 |
| D'Aiuto, F | 1 |
| Aljohani, S | 1 |
| Vescovi, P | 2 |
| Manfredi, M | 2 |
| Musciotto, A | 1 |
| Di Fede, O | 1 |
| Campisi, G | 1 |
| Chung, DJ | 1 |
| Park, YD | 1 |
| Grey, A | 1 |
| Cheung, A | 1 |
| Seeman, E | 1 |
| Pazianas, M | 1 |
| Chtioui, H | 1 |
| Lamine, F | 1 |
| Daghfous, R | 1 |
| Alloh Amichia, YC | 1 |
| Le Bars, P | 1 |
| Giumelli, B | 1 |
| Soueidan, A | 1 |
| Conte-Neto, N | 1 |
| Bastos, AS | 1 |
| Spolidorio, LC | 1 |
| Marcantonio, RA | 1 |
| Marcantonio, E | 1 |
| Kang, HS | 1 |
| Lee, JW | 1 |
| Kim, JS | 1 |
| Sharma, V | 1 |
| Nagaraj, S | 1 |
| Choksey, U | 1 |
| Hegde, A | 1 |
| Samant, R | 1 |
| Balakrishnan, C | 1 |
| Bartl, R | 1 |
| Weinstein, RS | 1 |
| Scully, C | 1 |
| Brooke, AE | 1 |
| Jureus, J | 1 |
| Lindstrand, A | 1 |
| Geijer, M | 1 |
| Roberts, D | 1 |
| Tägil, M | 2 |
| Ruggiero, SL | 1 |
| Mehrotra, B | 1 |
| Astrand, J | 1 |
| Westman, L | 1 |
| Aspenberg, P | 1 |
| Carter, G | 1 |
| Goss, AN | 1 |
| Doecke, C | 1 |
| Hande, K | 1 |
| Richardson, PG | 1 |
| Sarathy, AP | 1 |
| Bourgeois, SL | 1 |
| Goodell, GG | 1 |
| Marx, RE | 3 |
| Sawatari, Y | 1 |
| Fortin, M | 1 |
| Broumand, V | 1 |
| Robb-Nicholson, C | 2 |
| Alexander, RE | 1 |
| Marunick, M | 1 |
| Gordon, S | 1 |
| Nase, JB | 1 |
| Suzuki, JB | 1 |
| Ponte Fernández, N | 1 |
| Estefania Fresco, R | 1 |
| Aguirre Urizar, JM | 1 |
| Talbi, M | 1 |
| Carrie, F | 1 |
| Meley, M | 1 |
| Bobba, RS | 1 |
| Beattie, K | 1 |
| Parkinson, B | 1 |
| Kumbhare, D | 1 |
| Adachi, JD | 1 |
| Nastro, E | 1 |
| Musolino, C | 1 |
| Allegra, A | 1 |
| Oteri, G | 1 |
| Cicciù, M | 1 |
| Alonci, A | 1 |
| Quartarone, E | 1 |
| Alati, C | 1 |
| De Ponte, FS | 1 |
| Merigo, E | 1 |
| Meleti, M | 1 |
| Guidotti, R | 1 |
| Ripasarti, A | 1 |
| Zanzucchi, E | 1 |
| D'Aleo, P | 1 |
| Corradi, D | 1 |
| Corcione, L | 1 |
| Sesenna, E | 1 |
| Ferrari, S | 1 |
| Poli, T | 1 |
| Bonaninil, M | 1 |
| Rutkowski, JL | 1 |
| Johnson, DA | 1 |
| Smith, DM | 1 |
| Harper, RP | 1 |
| Fung, E | 1 |
| Letonturier, P | 1 |
| Khosa, AD | 1 |
| Nayyar, MS | 1 |
| Beirne, JC | 1 |
| Ruan, M | 1 |
| Ji, T | 1 |
| Zhang, CP | 1 |
| Malden, NJ | 1 |
| Pai, AY | 1 |
| Løkken, P | 1 |
| Skoglund, LA | 1 |
| Skjelbred, P | 1 |
| Strampel, W | 1 |
| Emkey, R | 1 |
| Civitelli, R | 1 |
| Fugazzotto, PA | 1 |
| Lightfoot, WS | 1 |
| Jaffin, R | 1 |
| Kumar, A | 1 |
| Levin, L | 1 |
| Laviv, A | 1 |
| Schwartz-Arad, D | 1 |
| Cillo, JE | 1 |
| Ulloa, JJ | 1 |
| Lee, CY | 1 |
| David, T | 1 |
| Nishime, M | 1 |
| Bianchi, ML | 1 |
| Limonta, C | 1 |
| Frasunkiewicz, J | 1 |
| Biggioggero, M | 1 |
| Vai, S | 1 |
| Khan, A | 1 |
| Udvardy, E | 1 |
| Redl, P | 1 |
| Márton, I | 1 |
| Engroff, SL | 1 |
| Coletti, D | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized Controlled Trial of Cesamet(R) (Nabilone) for the Prevention of Postoperative Nausea and Vomiting in Elective Surgery[NCT02115529] | Phase 2 | 331 participants (Actual) | Interventional | 2014-04-30 | Completed | ||
| The Use of Genex in the Management of Early-Stage Osteonecrosis of the Femoral Head[NCT05706909] | 20 participants (Anticipated) | Observational | 2023-02-08 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
16 reviews available for alendronate and Osteonecrosis
| Article | Year |
|---|---|
"Spontaneous" medication-related osteonecrosis of the jaw; two case reports and a systematic review.
Topics: Aged; Alendronate; Antineoplastic Agents; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone D | 2018 |
Important aspects concerning alendronate-related osteonecrosis of the jaws: a literature review.
Topics: Alendronate; Bone Density Conservation Agents; Humans; Jaw Diseases; Osteonecrosis | 2015 |
Efficacy of alendronate for preventing collapse of femoral head in adult patients with nontraumatic osteonecrosis.
Topics: Alendronate; Bone Density Conservation Agents; Femur Head; Humans; Lithotripsy; Osteonecrosis; Treat | 2014 |
QUESTION 1: Should we be using bisphosphonates for osteonecrosis complicating childhood acute lymphoblastic leukaemia?
Topics: Adolescent; Alendronate; Antineoplastic Agents; Bone Density Conservation Agents; Diphosphonates; Fe | 2016 |
Bisphosphonates for postmenopausal osteoporosis: determining duration of treatment.
Topics: Alendronate; Animals; Bone Density Conservation Agents; Diphosphonates; Etidronic Acid; Female; Frac | 2009 |
[Alendronate for treatment of osteoporoses].
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Evidence-Based Medicine; Femoral Fractu | 2009 |
Review of osteoporosis pharmacotherapy for geriatric patients.
Topics: Aged; Alendronate; Bone Density; Calcitonin; Calcium, Dietary; Diphosphonates; Economics, Pharmaceut | 2009 |
Osteonecrosis of the jaw and the role of macrophages.
Topics: Alendronate; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bone | 2011 |
Glucocorticoid-induced osteonecrosis.
Topics: Adult; Alendronate; Animals; Anti-Inflammatory Agents; Apoptosis; Bone Density Conservation Agents; | 2012 |
Glucocorticoid-induced osteonecrosis.
Topics: Adult; Alendronate; Animals; Anti-Inflammatory Agents; Apoptosis; Bone Density Conservation Agents; | 2012 |
Glucocorticoid-induced osteonecrosis.
Topics: Adult; Alendronate; Animals; Anti-Inflammatory Agents; Apoptosis; Bone Density Conservation Agents; | 2012 |
Glucocorticoid-induced osteonecrosis.
Topics: Adult; Alendronate; Animals; Anti-Inflammatory Agents; Apoptosis; Bone Density Conservation Agents; | 2012 |
Bisphosphonates and oral pathology I. General and preventive aspects.
Topics: Administration, Oral; Alendronate; Antibiotic Prophylaxis; Bone Density Conservation Agents; Bone Re | 2006 |
Tolerability of different dosing regimens of bisphosphonates for the treatment of osteoporosis and malignant bone disease.
Topics: Alendronate; Animals; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Etidronic Ac | 2006 |
Osteochemonecrosis of jaws and bisphosphonates.
Topics: Alendronate; Bone Density Conservation Agents; Etidronic Acid; Humans; Jaw; Osteonecrosis; Osteoporo | 2007 |
[Diphosphonate therapy and osteonecrosis of the jaw].
Topics: Aged; Alendronate; Bone Density Conservation Agents; Dental Care; Diphosphonates; Female; Humans; Ja | 2007 |
Safety considerations with bisphosphonates for the treatment of osteoporosis.
Topics: Acute-Phase Reaction; Administration, Oral; Alendronate; Bone Density Conservation Agents; Diphospho | 2007 |
Use of platelet-rich plasma in the management of oral biphosphonate-associated osteonecrosis of the jaw: a report of 2 cases.
Topics: Actinomycosis; Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Diphosphonate | 2007 |
[Osteonecrosis of the jaw developing during bisphosphonate treatment].
Topics: Alendronate; Anti-Infective Agents; Bone Density Conservation Agents; Bone Neoplasms; Bone Remodelin | 2008 |
3 trials available for alendronate and Osteonecrosis
| Article | Year |
|---|---|
Higher incidence of Osteonecrosis of the Jaw (ONJ) in patients with metastatic castration resistant prostate cancer treated with anti-angiogenic agents.
Topics: Adult; Aged; Alendronate; Angiogenesis Inhibitors; Diphosphonates; Humans; Ibandronic Acid; Incidenc | 2009 |
Clinical investigation of C-terminal cross-linking telopeptide test in prevention and management of bisphosphonate-associated osteonecrosis of the jaws.
Topics: Administration, Oral; Age Factors; Aged; Aged, 80 and over; Alendronate; Biomarkers; Bone Density Co | 2009 |
Use of bisphosphonates for the treatment of osteonecrosis as a complication of therapy for childhood acute lymphoblastic leukaemia (ALL).
Topics: Administration, Oral; Adolescent; Adrenal Cortex Hormones; Alendronate; Antineoplastic Combined Chem | 2010 |
88 other studies available for alendronate and Osteonecrosis
| Article | Year |
|---|---|
Osteonecrosis and spontaneous exfoliation of dental implants associated with oral bisphosphonate therapy: a case report.
Topics: Alendronate; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; D | 2020 |
Alendronate Alleviated Femoral Head Necrosis and Upregulated BMP2/EIF2AK3/EIF2A/ATF4 Pathway in Liquid Nitrogen Treated Rats.
Topics: Activating Transcription Factor 4; Alendronate; Animals; Bone Morphogenetic Protein 2; eIF-2 Kinase; | 2021 |
Anterolateral hip pain · no specific injury · Dx?
Topics: Alendronate; Arthralgia; Athletes; Bone Density Conservation Agents; Glucocorticoids; Hip Joint; Hoc | 2018 |
Bisphosphonate combination therapy for non-femoral avascular necrosis.
Topics: Administration, Intravenous; Administration, Oral; Adolescent; Adult; Aged; Alendronate; Bone Densit | 2019 |
Atypical femoral fractures shortly after osteonecrosis of the jaw in a postmenopausal woman taking alendronate for osteoporosis.
Topics: Administration, Oral; Alendronate; Bone Density Conservation Agents; Female; Femoral Fractures; Huma | 2013 |
Core decompression and alendronate treatment of the osteonecrotic rat femoral head: computer-assisted analysis.
Topics: Alendronate; Animals; Bone Density Conservation Agents; Combined Modality Therapy; Decompression, Su | 2013 |
Osteonecrosis of the jaw in Sweden associated with the oral use of bisphosphonate.
Topics: Administration, Oral; Age Factors; Aged; Aged, 80 and over; Alendronate; Bisphosphonate-Associated O | 2014 |
Spontaneous osteonecrosis of the knee: an unusual cause of knee pain.
Topics: Acute Disease; Adult; Alendronate; Arthralgia; Diclofenac; Disease Progression; Humans; Knee Joint; | 2014 |
Comment on "Efficacy of Alendronate for Preventing Collapse of Femoral Head in Adult Patients with Nontraumatic Osteonecrosis".
Topics: Alendronate; Bone Density Conservation Agents; Femur Head; Humans; Osteonecrosis | 2015 |
An osteonecrosis model induced by oral bisphosphonate in ovariectomised rats.
Topics: Administration, Oral; Alendronate; Animals; Bone Density Conservation Agents; Disease Models, Animal | 2015 |
Impact of selective alveolar decortication on bisphosphonate burdened alveolar bone during orthodontic tooth movement.
Topics: Alendronate; Alveolar Process; Animals; Bone Remodeling; Electron Probe Microanalysis; Female; Maxil | 2015 |
Epidemiological study of alendronate-related osteonecrosis of the jaw in the southeast of Scotland.
Topics: Aged; Aged, 80 and over; Alendronate; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Densi | 2016 |
Bisphosphonate-related osteonecrosis of the jaws--report of 2 cases and strategies on prevention and management.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Female; Humans; | 2008 |
Bisphosphonate-induced osteonecrosis of the jaws, bone markers, and a hypothesized candidate gene.
Topics: Alendronate; Biomarkers; Bone and Bones; Bone Density Conservation Agents; Collagen Type I; Cysteine | 2009 |
Oral bisphosphonate use and the prevalence of osteonecrosis of the jaw: an institutional inquiry.
Topics: Administration, Oral; Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Female | 2009 |
Is your knowledge up-to-date? Bisphosphonate-related osteonecrosis of the jaw.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Denture, Complete, Upper; Diphosphonates; Femal | 2008 |
Evidence-based dentistry and the concept of harm.
Topics: Alendronate; Bone Density Conservation Agents; Chronic Periodontitis; Clinical Competence; Databases | 2009 |
Bisphosphonates and low-impact femoral fractures: current evidence on alendronate-fracture risk.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Bone Resorption; Drug Administration Schedule; | 2009 |
Bisphosphonate-related osteonecrosis of the jaws: a single-center study of 101 patients.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alendronate; Angiogenesis Inhibitors; Anti-Bac | 2009 |
Bisphosphonates are not associated with vertebral osteonecrosis.
Topics: Adult; Aged; Aged, 80 and over; Alendronate; Bone Density; Diphosphonates; Female; Humans; Male; Mid | 2009 |
Outcome of surgical management of bisphosphonate-related osteonecrosis of the jaws: review of 33 surgical cases.
Topics: Adult; Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Diphosphonates; Femal | 2009 |
A compounded diagnosis: maxillary osteochemonecrosis in the setting of low dose radiotherapy.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Diagnosis, Differential; Diphosphonates; Female | 2009 |
Oral bisphosphonates.
Topics: Alendronate; Bone Density Conservation Agents; Female; Humans; Jaw Diseases; Osteonecrosis; Osteopor | 2009 |
Oral bisphosphonate-related osteonecrosis of the jaws: favorable outcome after bisphosphonate holiday.
Topics: Administration, Oral; Aged; Alendronate; Bone Density Conservation Agents; Collagen Type I; Drug Adm | 2009 |
Bisphosphonate administration prior to tooth extraction delays initial healing of the extraction socket in rats.
Topics: Alendronate; Animals; Bone Density Conservation Agents; Bone Resorption; Diphosphonates; Equipment D | 2009 |
Pathological fractures in patients caused by bisphosphonate-related osteonecrosis of the jaws: report of 3 cases.
Topics: Administration, Oral; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Diphosphonat | 2009 |
Intravenous bisphosphonate-related osteonecrosis of the jaw: bone scintigraphy as an early indicator.
Topics: Administration, Oral; Alendronate; Bone Density Conservation Agents; Diphosphonates; Early Diagnosis | 2009 |
Importance of microcracks in etiology of bisphosphonate-related osteonecrosis of the jaw: a possible pathogenetic model of symptomatic and non-symptomatic osteonecrosis of the jaw based on scanning electron microscopy findings.
Topics: Adult; Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Connective Tissue; Di | 2010 |
[Osteonecrosis of the jaw secondary to oral alendronate: Report of three cases].
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Diabetes Mellitus, Type 2; F | 2009 |
Mandibular necrosis in beagle dogs treated with bisphosphonates.
Topics: Alendronate; Alveolar Process; Animals; Bone Density Conservation Agents; Bone Matrix; Bone Remodeli | 2009 |
Battle over popular bone drug Fosamax bursts into court.
Topics: Alendronate; Bone Density Conservation Agents; Drug Industry; Humans; Jaw Diseases; Legislation, Dru | 2009 |
US judge rules Merck won't face "punitive damages" in first Fosamax case.
Topics: Alendronate; Bone Density Conservation Agents; Bone Remodeling; Drug Industry; Humans; Jaw Diseases; | 2009 |
Prevalence of osteonecrosis of the jaw in patients with oral bisphosphonate exposure.
Topics: Administration, Oral; Aged; Alendronate; Bone Density Conservation Agents; California; Cross-Section | 2010 |
Correlation between serum C-terminal cross-linking telopeptide of type I collagen and staging of oral bisphosphonate-related osteonecrosis of the jaws.
Topics: Administration, Oral; Aged; Aged, 80 and over; Alendronate; Biomarkers; Bone Density Conservation Ag | 2009 |
Inhibition of necrotic actions of nitrogen-containing bisphosphonates (NBPs) and their elimination from bone by etidronate (a non-NBP): a proposal for possible utilization of etidronate as a substitution drug for NBPs.
Topics: Alendronate; Animals; Bone Density Conservation Agents; Bone Resorption; Diphosphonates; Ear, Extern | 2010 |
Pathological fracture due to vertebral osteonecrosis associated with pancreatitis.
Topics: Alendronate; Bone and Bones; Bone Density Conservation Agents; Disease Progression; Fat Necrosis; Fr | 2011 |
Use of cone-beam computerized tomography for evaluation of bisphosphonate-associated osteonecrosis of the jaws.
Topics: Adult; Aged; Alendronate; Bone Density Conservation Agents; Cone-Beam Computed Tomography; Diphospho | 2010 |
Possible beneficial effect of bisphosphonates in osteonecrosis of the knee.
Topics: Alendronate; Alkaline Phosphatase; Amino Acids; Bone Density Conservation Agents; Bone Marrow Diseas | 2010 |
Resolution of oral bisphosphonate and steroid-related osteonecrosis of the jaw--a serial case analysis.
Topics: Actinomycosis; Administration, Oral; Aged; Aged, 80 and over; Alendronate; Anti-Bacterial Agents; Bo | 2010 |
Unusual case of a conservatively treated pathological fracture after sequestrectomy in a patient with long-term oral bisphosphonate use.
Topics: Administration, Oral; Aged; Alendronate; Anti-Bacterial Agents; Bone Density Conservation Agents; Di | 2011 |
How patients' lack of knowledge about oral bisphosphonates can interfere with medical and dental care.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alendronate; Bone Density; Bone Density Conser | 2010 |
Treatment outcomes in patients with bisphosphonate-related osteonecrosis of the jaws: a prospective study.
Topics: Aged; Alcohol Drinking; Alendronate; Anti-Bacterial Agents; Bone Density Conservation Agents; Chroni | 2010 |
Demineralization removes residual alendronate in allograft bone procured from donors with a history of bisphosphonate use.
Topics: Aged; Alendronate; Bone Demineralization Technique; Bone Density Conservation Agents; Bone Matrix; B | 2011 |
[Jaw osteonecrosis induced by oral biphosphonates: 12 cases].
Topics: Administration, Oral; Adrenal Cortex Hormones; Adult; Aged; Aged, 80 and over; Alendronate; Autoimmu | 2010 |
Association between bisphosphonates and jaw osteonecrosis: a study in Wistar rats.
Topics: Alendronate; Animals; Bone Density Conservation Agents; Diphosphonates; Disease Models, Animal; Drug | 2011 |
Bisphosphonates and atypical femoral fractures.
Topics: Alendronate; Bone Density Conservation Agents; Bone Resorption; Diphosphonates; Femoral Fractures; H | 2010 |
Nonexposed variant of bisphosphonate-associated osteonecrosis of the jaw: a case series.
Topics: Adult; Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Breast Neoplasms; Dip | 2010 |
Retrospective study of two biochemical markers for the risk assessment of oral bisphosphonate-related osteonecrosis of the jaws: can they be utilized as risk markers?
Topics: Administration, Oral; Aged; Aged, 80 and over; Alendronate; Biomarkers; Bone Density Conservation Ag | 2011 |
Teriparatide for bone loss in the jaw.
Topics: Alendronate; Bone Density Conservation Agents; Bone Regeneration; Combined Modality Therapy; Humans; | 2010 |
Teriparatide therapy for alendronate-associated osteonecrosis of the jaw.
Topics: Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Bone Regeneration; Female; Humans; | 2010 |
Teriparatide therapy for osteonecrosis of the jaw.
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Bone Regeneration; Drug Interactions; H | 2011 |
[Prosthetic rehabilitation after osteonecrosis of the jaws due to histiocytosis X and treatment with bisphosphonates apropos of a case].
Topics: Adult; Alendronate; Bone Density Conservation Agents; Denture Design; Denture, Partial, Fixed; Dentu | 2010 |
Oral bisphosphonate-related osteonecrosis of the jaws in rheumatoid arthritis patients: a critical discussion and two case reports.
Topics: Administration, Oral; Aged; Alendronate; Arthritis, Rheumatoid; Bone Density Conservation Agents; Di | 2011 |
Dental sinus tracts mimicking scrofuloderma: cutaneous presentation of underlying bisphosphonate-related osteonecrosis of the jaw.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Cutaneous Fistula; Diagnosis, Differential; Dip | 2011 |
Bisphosphonate-induced osteonecrosis of the jaw.
Topics: Adult; Aged; Alendronate; Bone Density Conservation Agents; Female; Humans; Jaw Diseases; Osteonecro | 2011 |
[Inflammation of the jaws during treatment with bisphosphonates].
Topics: Administration, Oral; Aged; Alendronate; Bone Density; Bone Density Conservation Agents; Bone Diseas | 2011 |
Images in clinical medicine. Halitosis and sensory loss.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Female; Halitosis; Humans; Mandibular Diseases; | 2012 |
Treatment of spontaneous osteonecrosis of the knee (SPONK) by a bisphosphonate.
Topics: Aged; Aged, 80 and over; Alendronate; Diphosphonates; Female; Humans; Knee Joint; Male; Middle Aged; | 2012 |
Ten years of alendronate treatment for osteoporosis in postmenopausal women.
Topics: Alendronate; Bone Regeneration; Female; Humans; Jaw; Osteonecrosis; Osteoporosis, Postmenopausal; Ri | 2004 |
Alendronate prevents collapse in mechanically loaded osteochondral grafts: a bone chamber study in rats.
Topics: Alendronate; Animals; Biomechanical Phenomena; Bone Remodeling; Bone Resorption; Bone Transplantatio | 2004 |
Alendronate (Fosamax) and risedronate (Actonel) revisited.
Topics: Alendronate; Bone Density; Bone Remodeling; Dose-Response Relationship, Drug; Etidronic Acid; Female | 2005 |
Bisphosphonates and avascular necrosis of the jaw: a possible association.
Topics: Aged; Aged, 80 and over; Alendronate; Anti-Inflammatory Agents; Diphosphonates; Female; Follow-Up St | 2005 |
Osteonecrosis of the jaw and bisphosphonates.
Topics: Alendronate; Animals; Diphosphonates; Humans; Imidazoles; Jaw Diseases; Osteonecrosis; Osteoporosis; | 2005 |
Bisphosphonate-associated osteonecrosis of the jaws and endodontic treatment: two case reports.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Diphosphonates; Humans; Imidazoles; Jaw Disease | 2005 |
Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment.
Topics: Abscess; Alendronate; Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Breas | 2005 |
[Osteonecrosis of the jaws as a possible adverse effect of the use of bisphosphonates].
Topics: Aged; Alendronate; Diphosphonates; Female; Follow-Up Studies; Humans; Imidazoles; Male; Mandibular D | 2005 |
By the way, doctor. I've heard that taking Fosamax for a long time causes the jawbone to deteriorate. Do you know anything about this?
Topics: Alendronate; Bone Density Conservation Agents; Diphosphonates; Female; Humans; Imidazoles; Osteoclas | 2005 |
Relationship between periodontal disease and systemic diseases.
Topics: Alendronate; Bone Density Conservation Agents; Contraindications; Dental Implantation, Endosseous; D | 2006 |
Prosthodontic treatment during active osteonecrosis related to radiation and bisphosphonate therapy: a clinical report.
Topics: Alendronate; Bone Density Conservation Agents; Carcinoma, Squamous Cell; Cranial Irradiation; Dentur | 2006 |
Osteonecrosis of the jaw and oral bisphosphonate treatment.
Topics: Administration, Oral; Aged; Alendronate; Bone Density Conservation Agents; Debridement; Dental Carie | 2006 |
[Bisphosphonate-related bilateral mandibular osteochemonecrosis with pathological fracture of the horizontal ramus].
Topics: Aged; Alendronate; Bone Density Conservation Agents; Fractures, Spontaneous; Humans; Male; Mandibula | 2006 |
Bisphosphonate-associated osteonecrosis of the jaw in patients with multiple myeloma and breast cancer.
Topics: Alendronate; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Fem | 2007 |
Bone necrosis of the jaws associated with bisphosphonate treatment: a report of twenty-nine cases.
Topics: Aged; Aged, 80 and over; Alendronate; Anti-Bacterial Agents; Antifungal Agents; Bone Density Conserv | 2006 |
Clinical concerns of alendronate use.
Topics: Alendronate; Bone Density Conservation Agents; Bone Remodeling; Contraindications; Dose-Response Rel | 2007 |
By the way, doctor. I'm 60 and have osteoporosis. My doctor is recommending Fosamax, but I'm concerned about jawbone problems. Are there any other drugs I can take?
Topics: Alendronate; Bone Density Conservation Agents; Estrogen Replacement Therapy; Exercise; Female; Human | 2006 |
Resolution of bisphosphonate-associated osteonecrosis of the mandible: possible application for intermittent low-dose parathyroid hormone [rhPTH(1-34)].
Topics: Aged; Alendronate; Bone Density Conservation Agents; Clinical Protocols; Female; Humans; Injections, | 2007 |
[Questions and answers about bisphosphonates].
Topics: Administration, Oral; Age Factors; Alendronate; Bone Density; Bone Density Conservation Agents; Bone | 2007 |
Bisphosphonates. A cornerstone of osteoporosis treatment.
Topics: Alendronate; Bone Density Conservation Agents; Diphosphonates; Estrogen Replacement Therapy; Etidron | 2007 |
[Advances in the research of bisphosphonate-associated osteonecrosis of the jaws].
Topics: Alendronate; Biomedical Research; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density C | 2006 |
Oral bisphosphonate associated osteonecrosis of the jaws: three case reports.
Topics: Administration, Oral; Aged; Alendronate; Anti-Bacterial Agents; Bone Density Conservation Agents; Bo | 2007 |
Implant placement with or without simultaneous tooth extraction in patients taking oral bisphosphonates: postoperative healing, early follow-up, and the incidence of complications in two private practices.
Topics: Administration, Oral; Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Dental | 2007 |
Denture-related osteonecrosis of the maxilla associated with oral bisphosphonate treatment.
Topics: Administration, Oral; Aged; Alendronate; Bone Density Conservation Agents; Denture, Partial, Removab | 2007 |
Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment.
Topics: Alendronate; Biomarkers; Bone Density Conservation Agents; Collagen Type I; Diphosphonates; Etidroni | 2007 |
Comment on: Bisphosphonates and osteonecrosis of the jaw.
Topics: Administration, Oral; Adolescent; Adult; Alendronate; Child; Child, Preschool; Diphosphonates; Dose- | 2008 |
Osteonecrosis of the jaw: new developments in an old disease.
Topics: Alendronate; Bone Density Conservation Agents; Diphosphonates; Dose-Response Relationship, Drug; Eti | 2008 |
Mandible matrix necrosis in beagle dogs after 3 years of daily oral bisphosphonate treatment.
Topics: Administration, Oral; Alendronate; Analysis of Variance; Animals; Bone Density Conservation Agents; | 2008 |
Bisphosphonate related osteonecrosis of the palate: report of a case managed with free tissue transfer.
Topics: Administration, Oral; Aged; Alendronate; Anastomosis, Surgical; Bone Density Conservation Agents; Fe | 2008 |
Clinical concerns of alendronate use.
Topics: Adult Stem Cells; Alendronate; Bone Density Conservation Agents; Dose-Response Relationship, Drug; H | 2008 |